Welcome to our dedicated page for WEST PHARMACEUTICAL SERVICES SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on WEST PHARMACEUTICAL SERVICES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into WEST PHARMACEUTICAL SERVICES's regulatory disclosures and financial reporting.
BUTHMAN MARK A reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services Inc. director Mark A. Buthman received an equity award of 791 shares of common stock. The shares were granted at a price of $0.00 per share as a form of compensation, not an open-market purchase.
These shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting. After this grant, Buthman directly holds a total of 44,308.5494 shares of West Pharmaceutical common stock.
West Pharmaceutical Services, Inc. reported results of its 2026 annual shareholder meeting held virtually on May 4, 2026. Shareholders elected eleven directors to serve until the 2027 meeting and approved, on a non-binding basis, compensation for named executive officers.
As of the February 27, 2026 record date, there were 72,081,610 common shares outstanding, and 66,193,322 shares, or 91.83%, were represented at the meeting. Shareholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the 2026 fiscal year and voted against a shareholder proposal seeking an Independent Board Chair Policy.
West Pharmaceutical Services Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 5,397,791 shares of Common Stock, representing 7.48% of the class. The filing lists sole voting power for 714,505 shares and sole dispositive power for 5,397,791 shares. The filing is signed by Ashley Grim as Head of Global Fund Administration.
West Pharmaceutical Services Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 4,102,674 shares of Common Stock, representing 5.69% of the class as of 03/31/2026. Vanguard Portfolio Management indicates sole dispositive power over 4,102,674 shares and sole voting power over 8,665 shares. The filing describes holdings managed across Vanguard affiliates and notes the ownership reflects securities held by Vanguard funds and client accounts.
West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite exercised stock options and sold shares of common stock. On April 27, she exercised options to acquire 2,817 shares at $83.47 per share and then sold 2,817 shares in an open-market transaction at a weighted average price of $305.2018 per share.
After these transactions, she directly holds 16,828.4906 shares of common stock and indirectly holds 4,966.6170 shares through a Non-Qualified Deferred Compensation Plan, showing she retains a meaningful equity stake in the company despite the net sale.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised stock options for 896 shares of common stock at $173.22 per share and on the same day sold 896 shares in an open-market sale at a weighted average price of $300.6688. After these transactions, he directly holds 1,522.81 shares.
West Pharmaceutical Services reported a strong first quarter of 2026 and raised its full-year outlook. Net sales reached $844.9 million, up 21.0% from a year earlier, with organic growth of 15.3%. Diluted EPS rose to $1.92, a 56.1% increase, and adjusted-diluted EPS climbed 46.9% to $2.13 as margins improved.
Growth was driven by the Proprietary Products segment, particularly High-Value Product components and delivery devices, and by demand tied to GLP‑1 obesity and diabetes treatments. Management now guides 2026 net sales to $3.295–$3.350 billion and adjusted-diluted EPS to $8.40–$8.75, both above previous ranges. During the quarter, the company generated free cash flow of $47.2 million and repurchased 1.2 million shares for $297.6 million.
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Janet Brutschea Haugen received a grant of 52 Phantom Stock Units tied to common stock. The units were valued at $250.64 per unit, bringing her total Phantom Stock Units to about 260.494 held directly.
Footnote disclosures state that Phantom Stock Units will be settled in shares of stock when she terminates service as a director. A separate line shows she directly holds 1,321.258 shares of common stock. Another footnote notes 1,071 restricted stock units and dividend equivalents that vest in full on the date of the next annual shareholder meeting.
The Vanguard Group filed an Amendment to its Schedule 13G/A reporting 0 shares beneficially owned of West Pharmaceutical Services Inc common stock, representing 0% of the class. The filing notes an internal realignment on January 12, 2026 after which certain Vanguard subsidiaries report holdings separately.